Generic Sensipar Availability
Last updated on May 7, 2025.
Sensipar is a brand name of cinacalcet, approved by the FDA in the following formulation(s):
SENSIPAR (cinacalcet hydrochloride - tablet;oral)
-
Manufacturer: AMGEN
Approval date: March 8, 2004
Strength(s): EQ 90MG BASE (discontinued) [RLD], EQ 30MG BASE (discontinued) [RLD], EQ 60MG BASE (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sensipar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Rapid dissolution formulation of a calcium receptor-active compound
Patent 7,829,595
Issued: November 9, 2010
Inventor(s): Lawrence; Glen Gary et al.
Assignee(s): Amgen Inc. (Thousand Oaks, CA)The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.
Patent expiration dates:
- September 22, 2026✓✓
- September 22, 2026
-
Rapid dissolution formulation of a calcium receptor-active compound
Patent 9,375,405
Issued: June 28, 2016
Inventor(s): Lawrence Glen Gary & Alvarez Francisco J. & Lin Hung-Ren H. & Ju Tzuchi R.
Assignee(s): Amgen, Inc.The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.
Patent expiration dates:
- September 22, 2026✓
- September 22, 2026
More about Sensipar (cinacalcet)
- Sensipar consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (9)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: calcimimetics
- Breastfeeding
- En español
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
